Quality-of-life assessment in French patients with metastatic melanoma in real life

Archive ouverte

Kandel, Marguerite | Dalle, Stéphane | Bardet, Aurélie | Allayous, Clara | Mortier, Laurent | Dutriaux, Caroline | Guillot, Bernard | Leccia, Marie Thérèse | Dalac, Sophie | Legoupil, Délphine | Saiag, Phillippe | Montaudie, Henri | Arnault, Jean Philippe | Brunet-Possenti, Florence | Grob, Jean Jacques | Dequatrebarbes, Julie | Beylot-Barry, Marie | Lesimple, Thierry P. | Aubin, François F. | Maubec, Eve | Granel-Brocard, Florence | Stoebner, Pierre Emmanuel | Dupuy, Alain | Dreno, Brigitte | Michiels, Stefan | Lebbe, Célèste | Borget, Isabelle

Edité par CCSD ; Wiley -

International audience. Background: Significant progress was recently observed in the treatment of metastatic melanoma (MM). With >50% of patients now reaching a second line of treatment and a significant improvement in the survival rate, an assessment of quality of life (QoL) during the whole course of the disease becomes necessary. The objective of this study was to describe the QoL of patients with MM in France, from their diagnosis of advanced disease to their death, in real life. Methods: QoL data were collected through MelBase, a prospective, French, multicentric cohort dedicated to the follow-up of adults with MM. QoL was assessed using the EuroQoL-5D questionnaire and the Functional Assessment of Cancer Treatment (FACT)-Melanoma questionnaire at the time of study inclusion, every 3 months, and at the time of each treatment change until death. To assess longitudinal changes from baseline to death, mixed-effect models for repeated-measures analyses were used to control for baseline covariates. Results: QoL was assessed in 1435 patients who were included in the study between 2013 and 2018. The median follow-up was 9.4 months, and 47% of patients died during follow-up. During first-line treatment, the model-based, mean utility score was 0.830 (95% CI, 0.818-0.843), the mean FACT-General score was 77.22 (95% CI, 76.23-78.22), and the mean FACT-Melanoma score was 129.46 (95% CI, 128.02-130.90). At the time of a change in treatment line, there was a decrease of −0.027 (95% CI, −0.03, −0.02) in the utility score, −1.82 (95% CI, −1.88, −1.76) in the FACT-General score, and −2.98 (95% CI, −3.05, −2.91) in the FACT-Melanoma score compared with first-line treatment. Conclusions: In the MelBase cohort, the QoL among patients with MM seems to be fairly stable over the whole disease course, although a small but significant decrease at time therapy is changed is observed.

Consulter en ligne

Suggestions

Du même auteur

Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in France

Archive ouverte | Kandel, Marguerite | CCSD

International audience. Nine drugs have been marketed for 10 years for the treatment of advanced melanoma (AM). With half of patients reaching a second line, the optimal sequence of treatments remains unclear. To in...

Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case–control study

Archive ouverte | Plaçais, Léo | CCSD

International audience. Objective To quantify the risk of immune-related adverse events (irAEs) in patients with pre-existing autoimmune disease (pAID) treated by immune checkpoint inhibitors (ICIs) for stage III or...

Radiotherapy and prognostic factors in adnexal carcinomas: A retrospective study of 657 patients from the French CARADERM network

Archive ouverte | Zagala, Robin | CCSD

International audience. Background: Cutaneous adnexal carcinomas are a heterogeneous group of rare neoplasms. Surgical excision is the first-line treatment in localized stage. The use and effectiveness of radiothera...

Chargement des enrichissements...